Celyad SA (CYAD) Scheduled to Post Earnings on Tuesday
Celyad SA (NASDAQ:CYAD) is scheduled to post its quarterly earnings results before the market opens on Tuesday, August 29th.
Celyad SA (NASDAQ CYAD) opened at 42.26 on Friday. Celyad SA has a 52 week low of $16.31 and a 52 week high of $48.93. The company’s 50-day moving average price is $39.37 and its 200 day moving average price is $34.37. The company’s market capitalization is $402.32 million.
A number of equities research analysts recently issued reports on CYAD shares. BidaskClub downgraded Celyad SA from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. ValuEngine raised Celyad SA from a “sell” rating to a “hold” rating in a research report on Thursday, June 29th.
About Celyad SA
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
Receive News & Stock Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related stocks with our FREE daily email newsletter.